FULL DETAILS (Read-only)  -> Click Here to Create PDF for Current Dataset of Trial
CTRI Number  CTRI/2025/08/093745 [Registered on: 27/08/2025] Trial Registered Prospectively
Last Modified On: 20/08/2025
Post Graduate Thesis  Yes 
Type of Trial  Interventional 
Type of Study   Drug
Ayurveda 
Study Design  Randomized, Parallel Group, Multiple Arm Trial 
Public Title of Study   This study aims to develop and standardize a user-friendly Ayurvedic device called the Dhuma Yantra for delivering (Dhuma Nasya), and to efficacy of Dhuma Nasya with Prototype, Navan Nasya, and classical Dhuma Nasya in the management of Ardhavabhedaka (Migraine) 
Scientific Title of Study   Development And Validation Of Dhuma Yantra And Its Comparative Clinical Evaluation With Navan Nasya And Dhuma Nasya With Classical Method In Ardhavabhedaka (Migraine): A Randomized Controlled Trial 
Trial Acronym  NIL 
Secondary IDs if Any  
Secondary ID  Identifier 
NIL  NIL 
 
Details of Principal Investigator or overall Trial Coordinator (multi-center study)  
Name  DR AJAY BALAUT 
Designation  PG SCHOLAR 
Affiliation  All India Institute of Ayurveda 
Address  OPD No. 6, Department of panchakarma, Ground floor, Hospital Block, All India Institute of Ayurveda, Gautampuri, Sarita Vihar, New Delhi

New Delhi
DELHI
110076
India 
Phone  9315602657  
Fax    
Email  ajaybalaut@gmail.com  
 
Details of Contact Person
Scientific Query
 
Name  Dr Santosh Kumar Bhatted 
Designation  Professor 
Affiliation  All India Institute of Ayurveda 
Address  Room no.703, Department of Panchakarma, Academic Block, All India Institute of Ayurveda, Gautampuri, Sarita Vihar, New Delhi

New Delhi
DELHI
110076
India 
Phone  9414048459  
Fax    
Email  santoshbhatted@rediffmail.com  
 
Details of Contact Person
Public Query
 
Name  Dr Santosh Kumar Bhatted 
Designation  Professor 
Affiliation  All India Institute of Ayurveda 
Address  Room no.703, Department of Panchakarma, Academic Block, All India Institute of Ayurveda, Gautampuri, Sarita Vihar, New Delhi

New Delhi
DELHI
110076
India 
Phone  9414048459  
Fax    
Email  santoshbhatted@rediffmail.com  
 
Source of Monetary or Material Support  
All India Institute of Ayurveda Gautampuri, Sarita Vihar, New Delhi 110076 
 
Primary Sponsor  
Name  All India Institute of Ayurveda 
Address  All India Institute of Ayurveda, Gautampuri, Sarita Vihar, New Delhi 
Type of Sponsor  Research institution and hospital 
 
Details of Secondary Sponsor  
Name  Address 
NIL  NIL 
 
Countries of Recruitment     India  
Sites of Study  
No of Sites = 1  
Name of Principal Investigator  Name of Site  Site Address  Phone/Fax/Email 
DR AJAY BALAUT   ALL INDIA INSTITUTE OF AYURVEDA HOSPITAL   Department of Panchakarma, OPD no. 6, Gautampuri, Sarita Vihar, New Delhi-110076 South West DELHI
New Delhi
DELHI 
09315602657

ajaybalaut@gmail.com 
 
Details of Ethics Committee  
No of Ethics Committees= 1  
Name of Committee  Approval Status 
Institutional Ethics Committee  Approved 
 
Regulatory Clearance Status from DCGI  
Status 
Not Applicable 
 
Health Condition / Problems Studied  
Health Type  Condition 
Patients  (1) ICD-10 Condition:G439||Migraine, unspecified. Ayurveda Condition: ARDHAVABEDAKAH,  
 
Intervention / Comparator Agent  
snoIntervention/ComparatorTypeDrug-TypeProcedure NameDetails
1Comparator ArmProcedure-dhUmapAnam, धूमपानम् (Procedure Reference: charak samhita , Procedure details: 3 or 4 sets of 3 inhalations and exhalations with shirovirechanadi dhumvarti with classical method. )
(1) Medicine Name: shirovirechanadi dhumvarti, Reference: charak samhita , Route: Nasal, Dosage Form: Bindu/ Drops/ Spray (Karna/ Nasa/ Netra/ Mukha), Dose: 4(NA), Frequency: od, Duration: 15 Days
2Comparator ArmProcedure-nasyam/ nastam, नस्यम्/ नस्तम् (Procedure Reference: charak samhita , Procedure details: Nasya for group A with anu taila 3 drops each nostril )
(1) Medicine Name: anu taila , Reference: charak samhita , Route: Nasal, Dosage Form: Bindu/ Drops/ Spray (Karna/ Nasa/ Netra/ Mukha), Dose: 3(drops), Frequency: od, Duration: 15 Days
3Intervention ArmProcedure-dhUmapAnam, धूमपानम् (Procedure Reference: charak samhita , Procedure details: 3 – 4 sets of 3 inhalations and exhalations with shirovirechanadi dhumvarti using prototype )
(1) Medicine Name: shirovirechanadi dhumvarti, Reference: charak samhita , Route: Nasal, Dosage Form: Bindu/ Drops/ Spray (Karna/ Nasa/ Netra/ Mukha), Dose: 4(NA), Frequency: od, Duration: 15 Days
 
Inclusion Criteria  
Age From  17.00 Year(s)
Age To  70.00 Year(s)
Gender  Both 
Details  a) Age : between 17 to 70 years
b) Gender: both
c) Socio-economic status: all
d) Willing to participate in the study.
e) Patients with the classical picture of ARDHAVBHEDAKA [Migraine] will be selected irrespective of Sex, Religion, and Profession.
 
 
ExclusionCriteria 
Details  (1) Patients who were not eligible for NASYA as per Ayurvedic Texts.
(2) Age less than 16 years and greater than 70 years.
(3) Referred pain in one half of the head due to disorders of the Eye, Ear, Nose, Throat, Teeth, etc., was excluded
(4) Patient having Familial Hemiplegic Migraine (FHM), Complicated Migraine, etc.
(5) Patient suffering from uncontrolled Diabetes, Tuberculosis, Hypertension, Malignancy, and/or any other General Debilitating Health condition.
(6) Patient who needed surgical intervention (Polyp, etc.)
 
 
Method of Generating Random Sequence   Computer generated randomization 
Method of Concealment   Not Applicable 
Blinding/Masking   Open Label 
Primary Outcome  
Outcome  TimePoints 
The improvement in patients will be assessed on the basis of relief in the signs and symptoms of the disease. For this purpose main signs and symptoms were given score according to their severity.   (DAY 0),(DAY 15),(DAY 45) 
 
Secondary Outcome  
Outcome  TimePoints 
Improvement in MSQ: MIGRAINE SPECIFIC QUALITY OF LIFE QUESTIONNAIRE and VAS(visual analogue scale).  (DAY 0),(DAY 15),(DAY 45) 
 
Target Sample Size   Total Sample Size="45"
Sample Size from India="45" 
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" 
Phase of Trial   Phase 2/ Phase 3 
Date of First Enrollment (India)   01/03/2026 
Date of Study Completion (India) Applicable only for Completed/Terminated trials 
Date of First Enrollment (Global)  Date Missing 
Date of Study Completion (Global) Applicable only for Completed/Terminated trials 
Estimated Duration of Trial   Years="1"
Months="0"
Days="0" 
Recruitment Status of Trial (Global)   Not Applicable 
Recruitment Status of Trial (India)  Not Yet Recruiting 
Publication Details   N/A 
Individual Participant Data (IPD) Sharing Statement

Will individual participant data (IPD) be shared publicly (including data dictionaries)?  

Response - NO
Brief Summary  

Need of the Study:

Migraine, known as Ardhavabhedaka in Ayurveda, affects approximately 14.12% to 25.2% of the Indian population, yet safe and sustainable alternatives to conventional therapies remain limited. Traditional Ayurvedic instruments, such as the Dhuma Yantra, lack standardization, leading to inconsistent results due to variations in size and material. Furthermore, there is insufficient comparative evidence between Shirovirechanadi Dhumavarti and Anu Taila Nasya, despite the latter’s established efficacy in symptom alleviation ranging from 45.4% to 76%. There is a growing necessity to integrate Ayurvedic therapies such as Dhuma and Nasya with modern clinical protocols, particularly for managing Vata-Kapha conditions. Although Nasya is a relatively simple procedure, Dhumavarti protocols should be simplified further to ensure better patient compliance. Migraine continues to be a widespread condition that remains inadequately managed, and current treatments like analgesics are not suitable for long-term use. A significant portion of the population continues to suffer due to the limitations of existing treatment options. Therefore, simplifying Ayurvedic smoke therapy methods can potentially improve patient experience and outcomes.

Rationality of the Study:

A comparative evaluation is essential, as existing research highlights the multiple benefits of Dhuma Nasya therapy, such as relief from headaches, migraines, and nasal congestion, while also balancing Vata and Kapha doshas. However, the absence of standardized devices and the lack of systematic comparison with well-established therapies like Navan Nasya have created a gap in evidence-based Ayurvedic practice. This study aims to address this gap by conducting a rigorous clinical evaluation of an improved Dhuma Yantra in comparison with proven traditional methods.

Objectives:

Primary:

 Development and validation of a standardized Dhuma Yantra.

 Evaluation of whether Anu Taila Nasya provides superior clinical outcomes in symptom reduction, assessed using a standardized scoring system, compared to Dhuma Nasya with Shirovirechanadi Dhumavarti administered through the classical method and prototype Dhuma Yantra.

Secondary:

Assessment of the impact of headaches on daily life using the HIT-6 questionnaire.

Improvement in the Migraine Specific Quality of Life Questionnaire (MSQ) and Visual Analogue Scale (VAS).

Methodology:

Type of Study: Triple-arm interventional clinical trial.
Study Design: Randomized comparative clinical trial.
Study Duration: Two and a half years.
Study Site: Patients attending the Panchakarma OPD and IPD at AIIA who meet the diagnostic criteria will be recruited.
Sampling Procedure: Probability sampling.
Randomization: Simple randomization.
Blinding or Masking: Open-label study.

 
Close